#POLB Poolbeg Pharma PLC – Appointment of Dr Adrian Kilcoyne to SAB March 12, 2026 – Posted in: Poolbeg Pharma (POLB)

Poolbeg Pharma (AIM: POLB, ‘Poolbeg’ or the ‘Company’), a clinical-stage biopharmaceutical company with a core focus on transforming the cancer immunotherapy field, announces the appointment of Dr Adrian Kilcoyne to its Scientific Advisory Board. Dr Kilcoyne brings over 20 years of clinical expertise with strategic drug development leadership, focusing on innovative therapies that address unmet medical needs in oncology and immunology and, in particular, brings deep knowledge of haematological malignancies, T-cell therapies and Cytokine Release Syndrome…

#POLB Poolbeg Pharma PLC – POLB 001 to feature in CRS research programme December 8, 2025 – Posted in: Poolbeg Pharma (POLB)

8 December 2025 – Poolbeg Pharma (AIM: POLB, ‘Poolbeg’ or the ‘Company’), a clinical-stage biopharmaceutical company with a core focus on transforming the cancer immunotherapy field, announces that the POLB 001 TOPICAL trial is to feature in a groundbreaking cancer immunotherapy-induced cytokine release syndrome (“CRS”) research programme. Poolbeg will act as the lead business partner, alongside Johnson & Johnson and other partners, on The University of Manchester and The Christie NHS Foundation Trust research programme supported by…

#POLB Poolbeg Pharma PLC – POLB 001 European Patent granted November 20, 2025 – Posted in: Poolbeg Pharma (POLB)

20 November 2025 – Poolbeg Pharma (AIM: POLB, ‘Poolbeg’ or the ‘Company’), a clinical-stage biopharmaceutical company with a core focus on transforming the cancer immunotherapy field, announces that the European Patent Office has granted Poolbeg’s European Immunomodulator II patent application covering POLB 001 for the treatment of severe influenza. POLB 001 is a potent and selective p38 MAP kinase inhibitor with strong potential across multiple disease areas, including the prevention and treatment of cancer immunotherapy-induced Cytokine Release Syndrome…

#HVO hVIVO PLC – >£5 million CRS contracts signed – Posted in: hVIVO (HVO)

hVIVO plc (AIM: HVO), a full-service early phase Contract Research Organisation (CRO) and the world leader in human challenge clinical trials, announces its German subsidiary CRS, has signed contracts worth over £5 million since September. The early-phase clinical trial service contracts have been signed with five clients, including two returning mid-sized German pharma customers reaffirming CRS’ strong reputation and long-standing relationships in Germany. These pharma partnerships, given their volume and consistency, strengthens the Group’s sales pipeline…

#POLB Poolbeg Pharma PLC – FDA Orphan Drug Designation granted for POLB 001 & AGM May 27, 2025 – Posted in: Poolbeg Pharma (POLB)

27 May 2025 – Poolbeg Pharma (AIM: POLB, ‘Poolbeg’ or the ‘Company’), a clinical-stage biopharmaceutical company focussed on the development of innovative medicines to address unmet medical needs, announces that the US Food and Drug Administration (“FDA”) has granted Orphan Drug Designation (“ODD”) to POLB 001 as an oral preventative therapy for T-cell engager bispecific antibody-induced Cytokine Release Syndrome (“CRS”). The FDA grants orphan status to support the development of medicines for rare disorders affecting less than…

#POLB Poolbeg Pharma PLC – POLB 001 data to be presented at ASH November 6, 2024 – Posted in: Poolbeg Pharma (POLB)

6 November 2024 – Poolbeg Pharma (AIM: POLB, ‘Poolbeg’ or the ‘Company’), a clinical-stage biopharmaceutical company focussed on the development and commercialisation of innovative medicines targeting diseases with a high unmet medical need, today announces that it will present a poster detailing POLB 001’s efficacy in reducing immunotherapy-induced CRS in an in vivo animal model, at the 66th American Society of Hematology (‘ASH’) Annual Meeting and Exposition, taking place 7-10 December 2024 in San Diego, California. Poolbeg’s poster presentation will provide insights into the results…

#POLB Poolbeg Pharma PLC – Interim results for the six months to 30 June 2024 September 18, 2024 – Posted in: Poolbeg Pharma (POLB)

Poolbeg Pharma plc – Interim results for the six months to 30 June 2024 Lead development candidate (POLB 001) on track with positive data demonstrating efficacy Independent research endorses potential US$10bn market opportunity for POLB 001 in cancer immunotherapy-induced CRS Patent portfolio significantly strengthened & expanded Continued focus on high value programmes & partnerships to develop & commercialise assets Strong Balance Sheet – cash balance of £10.1m Experienced leadership team with track record of…

#POLB Poolbeg Pharma PLC – Further data shows POLB001 potential in cancer CRS January 17, 2024 – Posted in: Blog, Poolbeg Pharma (POLB)

Further Data Confirms POLB 001’s Potential in Cancer Immunotherapy-Induced Cytokine Release Syndrome (CRS) Market opportunity estimated to be greater than US$1 billion Key highlights – Efficacy demonstrated in reducing cancer immunotherapy-induced CRS in an in vivo model – Data strengthens and facilitates the expansion of patent applications for POLB 001 in cancer immunotherapy-induced CRS – Independent Advisory Board supportive of POLB 001’s potential to both prevent and treat cancer immunotherapy-induced CRS –…

#POLB Poolbeg Pharma PLC – POLB 001 LPS Trial Data to be Presented at IUIS November 16, 2023 – Posted in: Blog, Poolbeg Pharma (POLB)

16 November 2023 – Poolbeg Pharma (AIM: POLB, OTCQB: POLBF, ‘Poolbeg’ or the ‘Company’), a biopharmaceutical company focussed on the development and commercialisation of innovative medicines targeting diseases with a high unmet medical need, announces that an abstract highlighting the potential of POLB 001 as a groundbreaking therapy has been accepted for presentation at the 18th International Congress of Immunology (‘IUIS’), to be held 27 November – 2 December 2023 in Cape Town, South Africa. IUIS is the world’s…

#POLB Poolbeg Pharma PLC – POLB 001 Oncology Programme Update Meeting November 1, 2023 – Posted in: Blog, Poolbeg Pharma (POLB)

1 November 2023 – Poolbeg Pharma (AIM: POLB, OTCQB: POLBF, ‘Poolbeg’ or the ‘Company’), a clinical-stage biopharmaceutical company targeting diseases with a high unmet medical need, announces that it will host a meeting for investors and analysts on the POLB 001 Oncology Programme on Monday 6 November 2023 at 2:00pm – 3:30pm GMT via the Investor Meet Company platform. The event will provide an update and greater detail on Poolbeg’s POLB 001 Oncology programme, which is…